The prognosis for NSCLC patients varies widely based on the stage at diagnosis, histological type, and the presence of genetic mutations. Early-stage NSCLC has a better prognosis, with five-year survival rates ranging from 60% to 80%. In contrast, advanced-stage NSCLC has a five-year survival rate of less than 10%. Advances in personalized medicine and ongoing clinical trials offer hope for improved outcomes in the future.
